Literature DB >> 23089374

The rapid recovery of 5-HT cell firing induced by the antidepressant vortioxetine involves 5-HT(3) receptor antagonism.

Cécile Bétry1, Alan L Pehrson, Adeline Etiévant, Bjarke Ebert, Connie Sánchez, Nasser Haddjeri.   

Abstract

The therapeutic effect of current antidepressant drugs appears after several weeks of treatment and a significant number of patients do not respond to treatment. Here, we report the effects of the multi-modal antidepressant vortioxetine (Lu AA21004), a 5-HT(3) and 5-HT(7) receptor antagonist, 5-HT(1B) receptor partial agonist, 5-HT(1A) receptor agonist and 5-HT transporter (SERT) inhibitor, on rat 5-HT neurotransmission. Using in vivo electrophysiological recordings in the dorsal raphe nucleus of anaesthetized rats, we assessed the acute and subchronic effects of vortioxetine and/or the selective 5-HT(3) receptor agonist, SR57227 or the selective 5-HT(1A) receptor agonist flesinoxan, on 5-HT neuronal firing activity. Using ex-vivo autoradiography, we correlated SERT occupancy and presumed 5-HT firing activity. The selective serotonin reuptake inhibitor, fluoxetine, was used as comparator. Importantly, the recovery of 5-HT neuronal firing was achieved after 1 d with vortioxetine and 14 d with fluoxetine. SR57227 delayed this recovery. In contrast, vortioxetine failed to alter the reducing action of 3 d treatment of flesinoxan. Acute dosing of vortioxetine inhibited neuronal firing activity more potently than fluoxetine. SR57227 prevented the suppressant effect of vortioxetine, but not of fluoxetine. In contrast, flesinoxan failed to modify the suppressant effect of vortioxetine acutely administered. Differently to fluoxetine, vortioxetine suppressed neuronal firing without saturating occupancy at the SERT. Vortioxetine produced a markedly faster recovery of 5-HT neuronal firing than fluoxetine. This is at least partly due to 5-HT(3) receptor antagonism of vortioxetine in association with its reduced SERT occupancy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23089374     DOI: 10.1017/S1461145712001058

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  22 in total

Review 1.  Vortioxetine: a review of its use in major depressive disorder.

Authors:  Karly P Garnock-Jones
Journal:  CNS Drugs       Date:  2014-09       Impact factor: 5.749

2.  Vortioxetine (brintellix): a new serotonergic antidepressant.

Authors:  Andrew D'Agostino; Clayton D English; Jose A Rey
Journal:  P T       Date:  2015-01

3.  Response of Htr3a knockout mice to antidepressant treatment and chronic stress.

Authors:  Vincent Martin; Armance Riffaud; Tevrasamy Marday; Charly Brouillard; Bernard Franc; Jean-Pol Tassin; Caroline Sevoz-Couche; Raymond Mongeau; Laurence Lanfumey
Journal:  Br J Pharmacol       Date:  2017-07-05       Impact factor: 8.739

4.  Vortioxetine: first global approval.

Authors:  Andrew Gibb; Emma D Deeks
Journal:  Drugs       Date:  2014-01       Impact factor: 9.546

5.  Astroglial Serotonin Receptors as the Central Target of Classic Antidepressants.

Authors:  Alexei Verkhratsky; Vladimir Parpura; Caterina Scuderi; Baoman Li
Journal:  Adv Neurobiol       Date:  2021

6.  The effects of Vilazodone, YL-0919 and Vortioxetine in hemiparkinsonian rats.

Authors:  Samantha Smith; Jordan Sergio; Michael Coyle; Kayla Elder; Ashley Centner; Sophie Cohen; Michelle Terry; Natalie Lipari; John Glinski; Emily Wheelis; Carla Budrow; Christopher Bishop
Journal:  Psychopharmacology (Berl)       Date:  2022-03-11       Impact factor: 4.530

7.  Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: Part 2, pharmacological interactions in rodents suggest a role of serotonin-3 receptor antagonism.

Authors:  Steven C Leiser; Deborah Iglesias-Bregna; Ligia Westrich; Alan L Pehrson; Connie Sanchez
Journal:  J Psychopharmacol       Date:  2015-07-14       Impact factor: 4.153

8.  Effects of acute and sustained administration of vortioxetine on the serotonin system in the hippocampus: electrophysiological studies in the rat brain.

Authors:  Mostafa El Mansari; Maurice Lecours; Pierre Blier
Journal:  Psychopharmacology (Berl)       Date:  2015-02-11       Impact factor: 4.530

9.  Trazodone regulates neurotrophic/growth factors, mitogen-activated protein kinases and lactate release in human primary astrocytes.

Authors:  Simona Daniele; Elisa Zappelli; Claudia Martini
Journal:  J Neuroinflammation       Date:  2015-12-01       Impact factor: 8.322

10.  Multi-modality: a new approach for the treatment of major depressive disorder.

Authors:  Elliott Richelson
Journal:  Int J Neuropsychopharmacol       Date:  2013-01-30       Impact factor: 5.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.